Free Trial

Q4 Earnings Estimate for Cresco Labs Issued By Roth Capital

Cresco Labs logo with Medical background

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Roth Capital issued their Q4 2024 EPS estimates for shares of Cresco Labs in a research note issued to investors on Sunday, November 10th. Roth Capital analyst W. Kirk expects that the company will post earnings per share of ($0.01) for the quarter. Roth Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Cresco Labs' current full-year earnings is ($0.19) per share. Roth Capital also issued estimates for Cresco Labs' Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.00 EPS and FY2025 earnings at ($0.01) EPS.

A number of other research analysts also recently issued reports on CRLBF. Ventum Cap Mkts upgraded shares of Cresco Labs to a "strong-buy" rating in a research report on Friday, August 9th. Needham & Company LLC restated a "hold" rating on shares of Cresco Labs in a report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $2.50.

Get Our Latest Stock Analysis on CRLBF

Cresco Labs Trading Up 14.3 %

OTCMKTS CRLBF traded up $0.18 during trading hours on Wednesday, reaching $1.44. The company's stock had a trading volume of 919,928 shares, compared to its average volume of 752,714. The firm has a fifty day simple moving average of $1.58 and a 200-day simple moving average of $1.71. The company has a debt-to-equity ratio of 1.76, a current ratio of 2.00 and a quick ratio of 1.30. Cresco Labs has a 52 week low of $1.02 and a 52 week high of $2.65. The stock has a market cap of $702.92 million, a P/E ratio of -7.10 and a beta of 1.88.

About Cresco Labs

(Get Free Report)

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.

Featured Stories

Earnings History and Estimates for Cresco Labs (OTCMKTS:CRLBF)

Should you invest $1,000 in Cresco Labs right now?

Before you consider Cresco Labs, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.

While Cresco Labs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?
SoundHound Stock Explodes Again – Is a Major Breakout Coming?
How Fintech Strategy at FinWise Bancorp and CEO Vision Are Driving 78% Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines